HomeAI · summaries
Storia in 2 fonti
Mirador unveils a piece of pipeline with drug from Kira to rival troubled Tavneos
Mirador Therapeutics licenses Kira Pharmaceuticals' KP-301 for $12M to treat ANCA-associated vasculitis, competing with Amgen's Tavneos.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Mirador Therapeutics Expands Precision Immunology Portfolio with Exclusive License to KP-301, a Long-Acting Anti-C5a Antibody
Mirador Therapeutics Expands Precision Immunology Portfolio with Exclusive License to KP-301, a Long-Acting Anti-C5a AntibodyAgreement with Kira Pharmaceuticals for exclusive…
- ·
endpoints.news
Mirador unveils a piece of pipeline with drug from Kira to rival troubled Tavneos
Mirador Therapeutics licenses Kira Pharmaceuticals' KP-301 for $12M to treat ANCA-associated vasculitis, competing with Amgen's Tavneos.